82
DAFTAR PUSTAKA
1. Breeze C. Early pregnancy bleeding. Aust J Gen Pract. 2016;45(5):283–6.
2. Prawirohardjo S. Nyeri Perut pada Kehamilan Muda. In: Ilmu Kebidanan.
Bina Pustaka; 2016. p. 659–66.
3. Leveno KJ, Spong CY, Dashe JS, Casey BM, Hoffman BL, Cunningham FG, et al. Abortion. In: Williams Obstetric. McGraw-Hill Education;
2018. p. 138–47.
4. Pranata S, Sadewo FS. Kejadian keguguran, kehamilan tidak direncanakan dan pengguguran di indonesia. Buletin Penelitian Sistem Kesehatan.
2012;15(4):180–92.
5. Defrin D, Ardinal A, Erkadius E. Perbedaan Rerata Kadar Progesterone- Induced Blocking Factor (PIBF) Serum Penderita Abortus Iminens dengan Kehamilan Normal. Jurnal Kesehatan Andalas. 2017;6(2):463.
6. Young BK. A multidisciplinary approach to pregnancy loss: The pregnancy loss prevention center. J Perinat Med. 2019;47(1):41–4.
7. Guttmacher Institute. Abortion in Asia. Vol. 6736. New York; 2017.
2016–2017 p.
8. Defrin D, Ardinal A, Erkadius E. Perbedaan Rerata Kadar Progesterone- Induced Blocking Factor (PIBF) Serum Penderita Abortus Iminens dengan Kehamilan Normal. Jurnal Kesehatan Andalas. 2017;6(2):463.
9. Leveno KJ, Spong CY, Dashe JS, Casey BM, Hoffman BL, Cunningham FG, et al. Abortion. In: Williams Obstetric. McGraw-Hill Education;
2018. p. 138–47.
10. Raghupathy R. Immunomodulation with progestogens as a therapeutic approach in pregnancy complications. Curr Med Res Pract.
2016;6(6):233–9.
11. Betris M. Analisis Faktor Risiko Kejadian Abortus Pada Ibu Hamil di Kota Pariaman. Jurnal Kesehatan Andalas. 2020;
12. Lim MK, Ku CW, Tan TC, Lee YHJ, Allen JC, Tan NS. Characterisation of serum progesterone and progesterone-induced blocking factor (PIBF) levels across trimesters in healthy pregnant women. Sci Rep.
2020;10(1):1–9.
13. Szekeres-bartho J. The Role of Extracellular Vesicles and PIBF in Embryo-Maternal. Front Immunol. 2018;9(December):1–9.
14. Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecological Endocrinology. 2017;33(6):421–4.
15. Lan Y, Yang X, Lei L, Liang Y, Wang S, Li Y. Progesterone-induced blocking factor-mediated Th1/Th2 balance correlates with fetal arrest in
women who underwent in vitro fertilization and embryo transfer.
Clinical Immunology. 2021;232.
16. Widya AC, Loho MF, Wantania JJE. The Role of Progesterone Induced Blocking Factor in Threatened Abortion Peran Progesterone Induced Blocking Factor pada Abortus Iminens. 2017;5(4).
17. John J. M. Paul. F. Personhoof status of the Human Zygore, Embryo, Fetus. Catholic Medical Association. 2017;
18. Bullard L, Browne P, Fellows S, Flanagon M. Embryonic and Fetal Developmental. American College of Obstetricians and Gynecologists.
2015;
19. Gundela M. Jean P.S. Louis M. et al. Embryonic and Early Fetal Development of the Human Neocortex. Journ Neuroscience. 2020;
20. Bullard L, Browne P, Fellows S, Flanagon M. Embryonic and Fetal Developmental. American College of Obstetricians and Gynecologists.
2015;
21. Shahbazi MN. Mechanisms of human embryo development: from cell fate to tissue shape and back. Development. 2020 Jul 15;147(14).
22. Gundela M. Jean P.S. Louis M. et al. Embryonic and Early Fetal Development of the Human Neocortex. Journ Neuroscience. 2020;
23. Yamada S, Samtani RR, Lee ES, Lockett E, Uwabe C, Shiota K, et al.
Developmental atlas of the early first trimester human embryo.
Developmental Dynamics. 2010 Jun;239(6):1585–95.
24. John J. M. Paul. F. Personhoof status of the Human Zygore, Embryo, Fetus. Catholic Medical Association. 2017;
25. Silveira PP. Fetal Growth and Brain Development—One Data Point Is Worth a Thousand Words, But Growth Trajectories Are Worth a Million.
JAMA Netw Open. 2021 Dec 9;4(12):e2139283.
26. Kemenkes RI. Abortus. In: Buku Saku Pelayanan Kesehatan Ibu di Fasilitas Kesehatan Dasar dan Rujukan. Jakarta; 2013. p. 84–91.
27. Prawirohardjo S. Nyeri Perut pada Kehamilan Muda. In: Ilmu Kebidanan.
Bina Pustaka; 2016. p. 659–66.
28. Keyhan S, Muasher L, Muasher SJ. Spontaneous Abortion and Recurrent Pregnancy Loss: Etiology, Diagnosis, Treatment. In: Comprehensive Gynecology. Seventh Ed. Jakarta: Elsevier; 2021. p. 329–347.e2.
29. Wilsher S, Newcombe JR, Allen WR (Twink). The immunolocalization of Galectin-1 and Progesterone-Induced Blocking Factor (PIBF) in equine trophoblast: Possible roles in trophoblast invasion and the immunological protection of pregnancy. Placenta. 2019;85(6):32–9.
30. Keyhan S, Muasher L, Muasher SJ. Spontaneous Abortion and Recurrent Pregnancy Loss: Etiology, Diagnosis, Treatment. In: Comprehensive Gynecology. Seventh Ed. Jakarta: Elsevier; 2021. p. 329–347.e2.
84
31. Clark A, Rapp A. Spontaneous Abortion. Treasure Island : StatPearls Publishing; 2022.
32. Rodgers SK, Chang C, DeBardeleben JT, Horrow MM. Normal and Abnormal US Findings in Early First-Trimester Pregnancy: Review of the Society of Radiologists in Ultrasound 2012 Consensus Panel Recommendations. RadioGraphics. 2015 Nov;35(7):2135–48.
33. Laopaiboon M, Lumbiganon P, Intarut N, Mori R, Ganchimeg T, Vogel JP, et al. Advanced maternal age and pregnancy outcomes: a multicountry assessment. BJOG. 2014;121 Suppl:49–56.
34. Ghimire PR, Akombi-Inyang BJ, Tannous C, Agho KE. Association between obesity and miscarriage among women of reproductive age in Nepal. PLoS One. 2020;15(8):1–13.
35. Katakam N, Nardo LG. Progestogens and Recurrent Miscarriage. In:
Progestogens in Obstetrics and Gynecology. 2021. p. 69–82.
36. Moradinazar M, Najafi F, Nazar ZM, Hamzeh B, Pasdar Y, Shakiba E.
Lifetime Prevalence of Abortion and Risk Factors in Women: Evidence from a Cohort Study. J Pregnancy. 2020;4(27).
37. Moradinazar M, Najafi F, Nazar ZM, Hamzeh B, Pasdar Y, Shakiba E.
Lifetime Prevalence of Abortion and Risk Factors in Women: Evidence from a Cohort Study. J Pregnancy. 2020;4(27).
38. Clark DA. Immunology of Pregnancy. Eighth Edi. Medical Complications During Pregnancy: Sixth Edition. Elsevier Inc.; 2013. 451–467 p.
39. Scarlet D. Chemical Information and Modeling. J Chem Inf Model.
2016;53(9):1689–99.
40. Clark DA. Immunology of Pregnancy. Eighth Edi. Medical Complications During Pregnancy: Sixth Edition. Elsevier Inc.; 2013. 451–467 p.
41. Szekeres-bartho J, Szekeres-bartho J. The Role of Progesterone in the Feto-Maternal Immunological Crosstalk. Front Immunol. 2018;9.
42. Morena MT De. Immunologic Changes During Pregnancy. Stiehm’s Immune Deficiencies. Elsevier Inc.; 2014. 815–822 p.
43. Scarlet D. Chemical Information and Modeling. J Chem Inf Model.
2016;53(9):1689–99.
44. Morena MT De. Immunologic Changes During Pregnancy. Stiehm’s Immune Deficiencies. Elsevier Inc.; 2014. 815–822 p.
45. Liang Q, Tong L, Xiang L, Shen S, Pan C, Zhang H. Distinct changes of in BTLA, ICOS, PD-1 and TIGIT expression on peripheral blood and decidual CD8+ T cells in women with unexplained recurrent abortion Etiology. J Oxford Reproduction. 2020;1(1):1–16.
46. Lim MK, Ku CW, Tan TC, Hao Y, Lee J, Allen JC, et al. Characterisation of serum progesterone and progesterone- induced blocking factor ( PIBF ) levels across trimesters in healthy pregnant women. Sci Rep.
2020;10(1):1–9.
47. Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J. T Helper ( Th ) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses. Front Immunol.
2020;11(8):1–14.
48. Szekeres-Bartho J, Schindler AE. Progestogens and immunology. Best Pract Res Clin Obstet Gynaecol. 2019;60(1):17–23.
49. Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J. T Helper ( Th ) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses. Front Immunol.
2020;11(8):1–14.
50. Raghupathy R. Cytokines and the Success or Failure of Pregnancy. In:
Mala Arora NM, editor. Recurrent Pregnancy Loss. Publishers, Jaypee Brothers Medical; 2018. p. 8–14.
51. Kemenkes RI. Abortus. In: Buku Saku Pelayanan Kesehatan Ibu di Fasilitas Kesehatan Dasar dan Rujukan. Jakarta; 2013. p. 84–91.
52. Lim MK, Ku CW, Tan TC, Lee YHJ, Allen JC, Tan NS. Characterisation of serum progesterone and progesterone-induced blocking factor (PIBF) levels across trimesters in healthy pregnant women. Sci Rep.
2020;10(1):1–9.
53. Szekeres-Bartho J, Schindler AE. Progestogens and immunology. Best Pract Res Clin Obstet Gynaecol. 2019;60(1):17–23.
54. Raghupathy R. Immunomodulation with progestogens as a therapeutic approach in pregnancy complications. Curr Med Res Pract.
2016;6(6):233–9.
55. Tesarik J, Conde-López C, Galán-Lázaro M, Mendoza-Tesarik R. Luteal Phase in Assisted Reproductive Technology. Frontiers in Reproductive Health. 2020 Dec 7;2.
56. Csabai T, Pallinger E, Kovacs AF, Miko E, Bognar Z, Szekeres-Bartho J.
Altered Immune Response and Implantation Failure in Progesterone- Induced Blocking Factor-Deficient Mice. Front Immunol.
2020;11(March):1–9.
57. Szekeres-bartho J, Stray-pedersen B, Fatuˇ Z, Polgar B, Vesna E. Lower Urinary and Serum Progesterone-Induced Blocking Factor in Women with Preterm Birth. 2016;117:66–9.
58. Wilsher S, Newcombe JR, Allen WR (Twink). The immunolocalization of Galectin-1 and Progesterone-Induced Blocking Factor (PIBF) in equine trophoblast: Possible roles in trophoblast invasion and the immunological protection of pregnancy. Placenta. 2019;85(6):32–9.
59. Hudić I, Stray-Pedersen B, Szekeres-Bartho J, Fatušić Z, Dizdarević- Hudić L, Tomić V, et al. Maternal serum progesterone-induced blocking factor (PIBF) in the prediction of preterm birth. J Reprod Immunol.
2015;109:36–40.
60. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF)
86
modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol. 2009;80(1–
2):91–9.
61. Witcher A, Comley K, Cottrell J, Cunningham M, Ibrahim T, LaMarca B, et al. Progesterone induced blocking factor inhibition causes inflammation and endothelial dysfunction in pregnant Sprague Dawley rats. Am J Obstet Gynecol. 2020;222(1):S5–6.
62. Witcher A, Comley K, Cottrell J, Cunningham M, Ibrahim T, LaMarca B, et al. Progesterone induced blocking factor inhibition causes inflammation and endothelial dysfunction in pregnant Sprague Dawley rats. Am J Obstet Gynecol. 2020;222(1):S5–6.
63. Hudić I, Stray-Pedersen B, Szekeres-Bartho J, Fatušić Z, Dizdarević- Hudić L, Tomić V, et al. Maternal serum progesterone-induced blocking factor (PIBF) in the prediction of preterm birth. J Reprod Immunol.
2015;109:36–40.
64. Szekeres-bartho J, Stray-pedersen B, Fatuˇ Z, Polgar B, Vesna E. Lower Urinary and Serum Progesterone-Induced Blocking Factor in Women with Preterm Birth. 2016;117:66–9.
65. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol. 2009;80(1–
2):91–9.
66. Widya AC, Loho MF, Wantania JJE. The Role of Progesterone Induced Blocking Factor in Threatened Abortion. Indonesian Journal of Obstetrics and Gynecology. 2017 Dec 8;193.
67. Hudić I, Fatušić Z. Progesterone – induced blocking factor (PIBF) and Th1/Th2 cytokine in women with threatened spontaneous abortion. J Perinat Med. 2009 Jan 1;37(4).
68. Kavalier F. Investigation of recurrent miscarriages. BMJ. 2005 Jul 16;331(7509):121–2.
69. Kalinka J, Szekeres-Bartho J. The Impact of Dydrogesterone Supplementation on Hormonal Profile and Progesterone-induced Blocking Factor Concentrations in Women with Threatened Abortion.
American Journal of Reproductive Immunology. 2005 Apr;53(4):166–71.
70. Raghupathy R. Cytokine imbalance in pregnancy complications and its modulation. Frontiers in Bioscience. 2008;13(13):985.
71. Abadi A, Baziad A, Hestiantoro A. The benefits of progesterone therapy in imminent abortion. Medical Journal of Indonesia. 2005 Nov 1;258.
72. Daya S. Luteal support: Progestogens for pregnancy protection. Maturitas.
2009 Dec;65:S29–34.
73. Szekeres-Bartho J. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Frontiers in Bioscience.
2008;13(13):1981.
74. Nardo LG, Sallam HN. Progesterone supplementation to prevent recurrent miscarriage and to reduce implantation failure in assisted reproduction cycles. Reprod Biomed Online. 2006 Jan;13(1):47–57.
75. Speroff L, Fritz MA. Clinical Gynecologic Endocrinologyand Infertility.
Seventh. Philadelphia : Williams & Wilkins; 2005.
76. Shah D, Nagarajan N. Luteal insufficiency in first trimester. Indian J Endocrinol Metab. 2013;17(1):44.
77. Polgár B, Nagy E, Mikó E, Varga P, Szekeres-Barthó J. Urinary Progesterone-Induced Blocking Factor Concentration Is Related to Pregnancy Outcome1. Biol Reprod. 2004 Nov 1;71(5):1699–705.
78. Kwak-Kim JYH. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Human Reproduction. 2003 Apr 1;18(4):767–73.
79. Andersen AMN. Maternal age and fetal loss: population based register linkage study. BMJ. 2000 Jun 24;320(7251):1708–12.
80. Stocco C, Telleria C, Gibori G. The Molecular Control of Corpus Luteum Formation, Function, and Regression. Endocr Rev. 2007 Feb 1;28(1):117–
49.
81. Duncan WC. The inadequate corpus luteum. Reproduction and Fertility.
2021 Feb 26;2(1):C1–7.
82. Mesiano S. Endocrinology of Human Pregnancy and Fetal-Placental Neuroendocrine Development. In: Yen and Jaffe’s Reproductive Endocrinology. Elsevier; 2019. p. 256-284.e9.
83. Dettmer AM, Rosenberg KL, Suomi SJ, Meyer JS, Novak MA. Associations between Parity, Hair Hormone Profiles during Pregnancy and Lactation, and Infant Development in Rhesus Monkeys (Macaca mulatta). PLoS One. 2015 Jul 14;10(7):e0131692.
84. Defrin D, Ardinal A, Erkadius E. Perbedaan Rerata Kadar Progesterone- Induced Blocking Factor (PIBF) Serum Penderita Abortus Iminens dengan Kehamilan Normal. Jurnal Kesehatan Andalas. 2017 Oct 12;6(2):463.
85. Szekeres-Bartho J, Polgar B. PIBF: The Double Edged Sword. Pregnancy and Tumor. American Journal of Reproductive Immunology. 2010 Mar;
86. Szekeres-Bartho J. The Role of Progesterone in Feto-Maternal Immunological Cross Talk. Medical Principles and Practice.
2018;27(4):301–7.
88
Lampiran 1. Kuesioner penelitian
DATA PASIEN Waktu pemeriksaan :
Tempat pengambilan data : Nomer sampel :
IDENTITAS :
Nama / No.CM :
Tempat , tanggal lahir : Pendidikan : SD/ SMP/ SMA/ S1/ S2
Agama : Pekerjaan : Tidak Bekerja/ PNS/ Swasta
Alamat :
No Telp/ HP :
Penghasilan : 1. < Rp.1.000.000
2. Rp. 1.000.000 – Rp. 2.000.000 3. Rp. 2.000.000 – Rp. 5.000.000 4. > Rp. 5.000.000
ANAMNESIS :
Keluhan :
HPHT :
Riw. Nikah :
Riw. Obstetri : G P A 1.
2.
3.
4.
Penggunaan obat progesteron : +/-
Riw. Penyakit Dahulu : Preeklampsia kehamilan sebelumnya : -/+
Diabetes melitus : -/+ Asma : -/+ Hipertensi : -/+
Penyakit tiroid : -/+ Infeksi kronis (sepsis) : -/+
Keganasan : -/+ Riwayat operasi +/- PEMERIKSAAN FISIK :
TD : HR : RR : T :
BB : TB : BMI :
KEPALA :
LEHER :
THORAK :
ABDOMEN :
EKSTERMITAS :
PEMERIKSAAN GINEKOLOGI Inspekulo /VT : Fluksus ( )/fluor ( ) Vulva/ uretra/ Vagina :
Portio :
Corpus Uterus : Adnexa parametrium : Cavum douglas :
PEMERIKSAN PENUNJANG :
USG :
Hasil Lab :
90 Lampiran 1. Kuesioner penelitian
KUESIONER
No. Pertanyaan Ya Tidak
1. Apakah anda hamil dengan usia <20 tahun atau >35 tahun?
2. Apakah ini hamil yang pertama?
3. Apakah ini hamil yang keempat atau lebih?
4. Apakah saat ini usia kehamilan anda <14 minggu?
5. Apakah anda memiliki kebiasaan aktivitas/pekerjaan yang berat?
6. Apakah anda memiliki riwayat jatuh/terbentur benda keras?
7. Apakah selama hamil anda merasa stress berlebih?
8. Apakah anda memiliki penyakit gula, tekanan darah tinggi kronis, gagal ginjal kronis, infeksi kronis, penyakit tiroid, penyakit serebrovaskuler sebelum kehamilan?
9. Apakah saat ini mengalami keadaan ancaman kematian janin dalam rahim?
10. Apakah sebelumnya anda pernah mengalami keadaan kematian janin dalam rahim?
Apakah anda memiliki riwayat penyakit genetik/keturunan?
11. Apakah suami anda memiliki riwayat penyakit genetik/keturunan?
12. Apakah suami anda memiliki riwayat penyakit anemia?
13. Apakah anda memiliki riwayat kelainan kongenital pada rahim?
14. Apakah anda memiliki riwayat kelemahan otot leher rahim?
15. Apakah anda memiliki riwayat keganasan organ genitalia?
15. Apakah anda memiliki riwayat penyakit polip serviks?
16. Apakah anda memiliki riwayat preeklampsia sebelumnya?
17. Apakah selama hamil anda rutin mengonsumsi suplemen seperti tablet tambah darah maupun kalsium?
18. Apakah anda menerima terapi progesteron selama kehamilan?
19. Apakah anda memiliki riwayat merokok, minum alkohol?
Lampiran 2. Ethical clearance
92 Lampiran 3. Izin penelitian
Lampiran 3. Izin penelitian
3(0(5,17$+.$%83$7(1-(3$5$
',1$63(1$1$0$102'$/'$13(/$<$1$17(53$'86$783,178 -O.DUWLQL1R-HSDUD3KRQH)D[
(PDLOGSPSWVSMHSDUD#JPDLOFRP -(3$5$
.(38786$1.(3$/$',1$63(1$1$0$102'$/'$1 3(/$<$1$17(53$'86$783,178
.$%83$7(1-(3$5$
12025 7(17$1*
,=,13(1(/,7,$1
%HUGDVDUNDQ 6XUDW 5HNRPHQGDVL 'DUL 81,9(56,7$6 ',321(*252 6(0$5$1* 1RPRU 8133 SHULKDO ,MLQ 3HQHOLWLDQ
0DNDGHQJDQLQLGLEHULNDQLMLQSHQHOLWLDQNHSDGD
1DPD 05H]D+LGD\DW 3HNHUMDDQ 'RNWHU 1,0
$ODPDW 3HODZDQ575:.HF3HODZDQ.DE6DURODQJXQ 1DPD/HPEDJD 8QLYHUVLWDV'LSRQHJRUR6HPDUDQJ
3HQDQJJXQJ-DZDE 'UGU+HUPLQD6XNPDQLQJW\DV0.HV6S5DG.
0DNVXGGDQ7XMXDQ 3HQHOLWLDQ
-XGXO3HQHOLWLDQ 3HUEHGDDQ5HUDWDNDGDU6HUXP3URJHVWHURQ,QGXFHG%ORFNLQJ)DFWRU3,%)
$ERUWXV,PPLQHQVGHQJDQNHKDPLODQQRUPDO $QJJRWD3HQHOLWLDQ
/RNDVL 568'5$.DUWLQL-HSDUD 'HQJDQ.HWHQWXDQbNHWHQWXDQVHEDJDLEHULNXW
3HODNVDQDDQ SHQHOLWLDQ WLGDN GLVDODKJXQDNDQ XQWXN WXMXDQ WHUWHQWX \DQJ GDSDW PHQJJDQJJX
VWDELOLWDVSHPHULQWDKDQ
6HEHOXPPHODNVDQDNDQSHQHOLWLDQODQJVXQJNHSDGDUHVSRQGHQKDUXVWHUOHELKGDKXOXPHODSRUNDQ
NHSDGD3LPSLQDQZLOD\DKVHWHPSDW
6HWHODK SHQHOLWLDQ VHOHVDL DJDU PHPEHULWDKX GDQ PHPEHULNDQ KDVLO SHQHOLWLDQ NHSDGD
%DNHVEDQJSRO.DEXSDWHQ-HSDUD
6XUDWNHWHUDQJDQSHQHOLWLDQLQLEHUODNXWDQJJDOVG
'LWHWDSNDQGL-HSDUD 3DGD7DQJJDO$SULO .(3$/$',1$63(1$1$0$102'$/'$1
3(/$<$1$17(53$'86$783,178 .$%83$7(1-(3$5$
+(5<<8/,<$172667306L 3HPELQD7N, 1,3
94 Lampiran 4. Statistik penelitian
Descriptives
Kelompok Statistic Std. Error
Usia Abortus Iminens Mean
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
Kontrol Mean
95% Confidence Interval for Mean
Lower Bound Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis PIBF Abortus Iminens Mean
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
Kontrol Mean
31.50 2.542 25.49
37.51 31.39 30.50 51.714 7.191 2 1 4 4 2 3 9
.387 .752
.018 1.481 34.75 3.750 22.82
46.68 34.89 36.00 56.250 7.500 2 5 4 2 1 7 1 4
- . 7 5 0 1.014 - . 7 1 5 2.619 69.1575 1.86179 64.7551
73.5599 69.2106 68.5700 27.730 5.26593 61.54 75.82 14.28 9.48
- . 0 0 3 .752 - 1 . 5 5 1 1.481 101.5225 7.33560
78.1773
Page 3
Descriptives
Kelompok Statistic Std. Error
PIBF
Kontrol
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
78.1773 124.8677 102.1372 107.0550 215.244 14.67120 79.88 112.10 32.22 24.89
- 1 . 8 0 4 1.014
3.377 2.619
Tests of Normality
Kelompok
Kolmogorov-Smirnova Shapiro-Wilk
Statistic d f Sig. Statistic d f Sig.
Usia Abortus Iminens Kontrol PIBF Abortus Iminens
Kontrol
.187 8 .200* .958 8 .790
.215 4 . .953 4 .735
.217 8 .200* .911 8 .362
.359 4 . .793 4 .090
This is a lower bound of the true significance.
*.
Lilliefors Significance Correction a.
Usia
Normal Q-Q Plots
Page 4
96
Descriptives
Kelompok Statistic Std. Error
PIBF Abortus Iminens
Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
Kontrol Mean
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
91.131 9.54625 53.00 69.85 16.85 .
1.723 1.225
. .
95.5867 7.69582 62.4742
128.6991 . 98.7500 177.677 13.32955 80.96 107.05 26.09 .
- 1 . 0 0 8 1.225
. .
Tests of Normality
Kelompok
Kolmogorov-Smirnova Shapiro-Wilk
Statistic d f Sig. Statistic d f Sig.
Usia Abortus Iminens Kontrol PIBF Abortus Iminens
Kontrol
.385 3 . .750 3 .000
.175 3 . 1.000 3 1.000
.373 3 . .779 3 .065
.260 3 . .958 3 .605
Lilliefors Significance Correction a.
Usia
Normal Q-Q Plots
Page 1 1
Independent Samples Test Levene's Test for Equality of
Variances
t-test for Equality of Means
F Sig. t d f
Usia Equal variances assumed Equal variances not assumed
PIBF Equal variances assumed Equal variances not assumed
.000 1.000 - . 7 2 8 1 0 .483
- . 7 1 7 5.861 .501
5.073 .048 - 5 . 7 6 7 1 0 .000
- 4 . 2 7 6 3.393 .018
Independent Samples Test
t-test for Equality of Means
Sig. (2-tailed)
Mean Difference
Std. Error Difference
95%
Confidence ...
Lower Usia Equal variances assumed
Equal variances not assumed
PIBF Equal variances assumed Equal variances not assumed
.483 - 3 . 2 5 0 4.461 - 1 3 . 1 9 0 6.690
.501 - 3 . 2 5 0 4.531 - 1 4 . 4 0 0 7.900
.000 - 3 2 . 3 6 5 0 0 5.61196 - 4 4 . 8 6 9 2 3 - 1 9 . 8 6 0 7 7 .018 - 3 2 . 3 6 5 0 0 7.56818 - 5 4 . 9 4 6 8 1 - 9 . 7 8 3 1 9
Independent Samples Test t-test for
Equality of ...
95% Confidence Interval of the ...
Upper Usia Equal variances assumed
Equal variances not assumed
PIBF Equal variances assumed Equal variances not assumed
6.690 7.900 - 1 9 . 8 6 0 7 7 - 9 . 7 8 3 1 9
USE ALL.
COMPUTE filter_$=(Usia_Gestasi = 8).
VARIABLE LABELS filter_$ 'Usia_Gestasi = 8 (FILTER)'.
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'.
Page 4 4
98
Case Processing Summary
Kelompok
Cases
Valid Missing Total
N Percent N Percent N Percent
Usia Abortus Iminens Kontrol PIBF Abortus Iminens
Kontrol
3 100.0% 0 0.0% 3 100.0%
3 100.0% 0 0.0% 3 100.0%
3 100.0% 0 0.0% 3 100.0%
3 100.0% 0 0.0% 3 100.0%
Descriptives
Kelompok Statistic Std. Error
Usia Abortus Iminens Mean
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis
Kontrol Mean
95% Confidence Interval for Mean
Lower Bound Upper Bound 5% Trimmed Mean
Median Variance Std. Deviation Minimum Maximum Range
Interquartile Range Skewness Kurtosis PIBF Abortus Iminens Mean
95% Confidence Interval
for Mean Lower Bound
Upper Bound 5% Trimmed Mean
Median
36.33 .667
33.46 39.20 . 37.00 1.333 1.155 3 5 3 7 2 .
- 1 . 7 3 2 1.225
. .
28.00 1.155 23.03
32.97 . 28.00 4.000 2.000 2 6 3 0 4 .
.000 1.225
. .
58.8333 5.51153 35.1191
82.5475 . 53.6500 91.131
Page 1 0
Lampiran 5. Hasil pengukuran PIBF
KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET, DAN TEKNOLOGI
UNIVERSITAS DIPONEGORO FAKULTAS KEDOKTERAN LABORATORIUM GAKI
Jalan Prof. Sudarto, S.H.
(Laboratorium Sentral FK Lantai 2) Tembalang Semarang Kode Pos 50275 Tel./Faks. (024) 76928010 www.fk.undip.ac.id│email:dean[at]fk.undip.ac.id
HASIL PEMERIKSAAN PIBF
“ Perbedaan Rerata Kadar Serum Progesteron-Induced Blocking Factor (PIBF) Abortus Imminens dengan Kehamilan Normal (Studi pada Kehamilan Trimester I) “
Peneliti : dr. Muhammad Reza Hidayat (PPDS I Obstetri – Ginekologi)
NO. NAMA HASIL PIBF
(ng/ml)
1. Ny. Uwaliyah 75,82
2. Ny. Maryatun 53,11
3. Ny. Anita Herawati 47,95
4. Ny. Nanik Rahayu 64,95
5. Ny. Siti Handayani 53,11
6. Ny. Mia Anggraini 48,70
7. Ny. Taslimah 61,54
8. Ny. Maya Mustikarini 58,24
9. Ny. Santoso 48,70
10. Ny. Nofik Mayasari 105,60
11. Ny. Avilia Ayu 114,25
12. Ny. Rianti 108,51
13. Ny. Hutri 124,68
14. Ny. Husnun Nuhlah 61,54
15. Ny. Rufita 48,70
16. Ny. Siti Ma’unah 49,03
17. Ny. Iswa Nur Mazidah 49,24
18. Ny. Eka Sriyanti 69,85
19. Ny. Isriyah 53,54
20. Ny. Nandifah 53,00
21. Ny. Erniyawati 53,65
22. Ny. Kukuh 56,21
23. Ny. Khoirun Nisa 53,11
24. Ny. Dwicha Novianti 61,54
25. Ny. Rofiah 74,43
26. Ny. Anik 68,57
27. Ny. Ani Nurcahyani 64,95
28. Ny. Avida istiqomah 74,43
29. Ny. Nia Putri Ayu 68,57
30. Ny. Khusnul Atika 70,70
31. Ny. Lina Setyara 61,54
32. Ny. Siti Nur Safitri 134,18
33. Ny. Rina Purnawati 142,71
34. Ny. Tantai 139,44
35. Ny. Khalifatul Aliyah 113,68
36. Ny. Musaqqif Ubaidah 80,96
37. Ny. Devi Achayani 107,05
38. Ny. Siti Fauzia 99,30
39. Ny. Eni Rohmawati 80,10
40. Ny. Lutfiyah 83,43
41. Ny. Nur Afifah 94,48
42. Ny. Dian Alawiyah 112,10
100
NO. NAMA HASIL PIBF
(ng/ml)
43. Ny. Robiatul Adawiyah 79,88
44. Ny. Mudayanik 138,24
45. Ny. Reza Farida 96,99
46. Ny. Solikhatun 112,10
47. Ny. Siti Munawaroh 98,75
48. Ny. Anisa 114,25
49. Ny. Khairun Nisa 111,43
50. Ny. Wahyu Listiyaningsih 191,14
51. Ny. Nur Istiqomah 98,20
52. Ny. Ernawati 139,68
53. Ny. Ayu Dewi Lestari 83,43
54. Ny. Erni Purwanti 106,94
Semarang, 21 Juli 2022
Koordinator Sub Lab. GAKI FK UNDIP
Prof. Dr. dr. Banundari Rachmawati, SpPK(K)
102
104
106 Lampiran 7. Dokumentasi penelitian
